皮肤性病诊疗学杂志2023，Vol.30Issue(6)：489-494,6.DOI:10.3969/j.issn.1674-8468.2023.06.002
间充质干细胞外泌体治疗玫瑰痤疮的疗效观察
Clinical observation on the therapeutic efficacy of mesenchymal stem cell-derived exosomes for rosacea
周佳 1殷珊 1易丽萍 1何琪蕾 1李沛徽 1易雷 1尹敏 1刘翔 1麦跃 1吴姗姗 1何加炜 1李苗苗 1李帅华 1周欢1
作者信息
- 1. 长沙美莱医疗美容医院,湖南 长沙 410000
- 折叠
摘要
Abstract
Objective To observe the therapeutic effects of mesenchymal stem cell-derived ex-osomes on rosacea.Methods Seventy-eight patients with rosacea,including 39 PPR type and 39 ETR type,were enrolled at the Changsha Mylike Cosmetic Hospital from January 2021 to January 2022.All patients were treated with microneedling infusion of mesenchymal stem cell-derived exo-somes(MSC-exo)once a month for three months.The clinical efficacy,adverse reactions,ery-thema assessment scale(CEA),patient physical evaluation(PSA),investigators'global assess-ment(IGA)scale and skin barrier function were compared between the two groups.Results Treatment with MSC-exo significantly decreased both CEA and IGA scales,EI and TEWL,while increasing stratum corneum hydration(P＜0.05 for all).After 3 treatments with MSC-exo,both CEA and IGA scales were higher in patients with ETR type than in that with PPR type(both P＜0.05).Both EI and TEWL were lower in patients with PPR than in that with ETR(P＜0.05).In contrast,both stratum corneum hydration levels and PSA were higher in patients with PPR than in that with ETR(P＜0.05).The effective rates in patients with PPR type and ETR type were 89.74％and 64.10％,respectively(x2=7.22,P=0.007).However,the adverse reaction rates were comparable between the two groups(x2=1.92,P=0.166).Conclusions Treat-ments with MSC-exo can significantly improve the skin condition and skin barrier function in pa-tients with rosacea.Compared with the ETR group,MSC-exo is more effective in improving skin condition in the PPR.关键词
玫瑰痤疮/间充质干细胞/外泌体/皮肤屏障/微针Key words
rosacea/mesenchymal stem cell/exosomes/skin barrier/microneedle引用本文复制引用
周佳,殷珊,易丽萍,何琪蕾,李沛徽,易雷,尹敏,刘翔,麦跃,吴姗姗,何加炜,李苗苗,李帅华,周欢..间充质干细胞外泌体治疗玫瑰痤疮的疗效观察[J].皮肤性病诊疗学杂志,2023,30(6):489-494,6.
